MX2023010067A - Piridinas sustituidas como inhibidores de dnmt1. - Google Patents

Piridinas sustituidas como inhibidores de dnmt1.

Info

Publication number
MX2023010067A
MX2023010067A MX2023010067A MX2023010067A MX2023010067A MX 2023010067 A MX2023010067 A MX 2023010067A MX 2023010067 A MX2023010067 A MX 2023010067A MX 2023010067 A MX2023010067 A MX 2023010067A MX 2023010067 A MX2023010067 A MX 2023010067A
Authority
MX
Mexico
Prior art keywords
dnmt1
substituted pyridines
inhibitors
compounds
activity
Prior art date
Application number
MX2023010067A
Other languages
English (en)
Inventor
Andrew B Benowitz
David T Fosbenner
Bryan Wayne King
Stuart Paul Romeril
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MX2023010067A publication Critical patent/MX2023010067A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84—Nitriles
    • C07D213/85—Nitriles in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La invención se refiere a derivados de piridina sustituidos que son inhibidores de la actividad de DNA metiltransferasa 1 (DNMT1). La invención también se refiere a las composiciones farmacéuticas que comprenden dichos compuestos y a los métodos de uso de dichos compuestos en el tratamiento del cáncer, síndromes precancerosos, trastornos por hemoglobinopatía beta y otras enfermedades asociadas a la actividad inadecuada de DNMT1.
MX2023010067A 2021-03-02 2022-02-24 Piridinas sustituidas como inhibidores de dnmt1. MX2023010067A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163155325P 2021-03-02 2021-03-02
PCT/IB2022/051637 WO2022185160A1 (en) 2021-03-02 2022-02-24 Substituted pyridines as dnmt1 inhibitors

Publications (1)

Publication Number Publication Date
MX2023010067A true MX2023010067A (es) 2023-09-06

Family

ID=80628728

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010067A MX2023010067A (es) 2021-03-02 2022-02-24 Piridinas sustituidas como inhibidores de dnmt1.

Country Status (15)

Country Link
US (2) US11771711B2 (es)
EP (1) EP4301733A1 (es)
JP (1) JP2024509529A (es)
KR (1) KR20230154230A (es)
CN (1) CN116917273A (es)
AR (1) AR124975A1 (es)
AU (1) AU2022230795A1 (es)
BR (1) BR112023017296A2 (es)
CA (1) CA3212345A1 (es)
CL (1) CL2023002577A1 (es)
CO (1) CO2023011641A2 (es)
IL (1) IL305427A (es)
MX (1) MX2023010067A (es)
TW (1) TW202302535A (es)
WO (1) WO2022185160A1 (es)

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
PL206832B1 (pl) 2000-05-19 2010-09-30 Corixa Corp Zastosowanie związków opartych na mono- i disacharydach
US7129219B2 (en) 2000-08-04 2006-10-31 Corixa Corporation Immunoeffector compounds
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
EP1525223B1 (en) 2002-06-13 2007-11-21 Crucell Holland B.V. Ox40 (=cd134) receptor agonists and therapeutic use
PT2206517T (pt) 2002-07-03 2023-11-07 Tasuku Honjo Composições de imunopotenciação contendo anticorpos anti-pd-l1
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
EP1591527B1 (en) 2003-01-23 2015-08-26 Ono Pharmaceutical Co., Ltd. Substance specific to human pd-1
ES2427646T5 (es) 2005-05-09 2017-08-22 Ono Pharmaceutical Co., Ltd. Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
MX2007015942A (es) 2005-07-01 2008-03-07 Medarex Inc Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
CN101861168B (zh) 2007-05-07 2014-07-02 米迪缪尼有限公司 抗-icos抗体及其在治疗肿瘤、移植和自身免疫病中的应用
RS53072B (en) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1
MX2010006466A (es) 2007-12-14 2010-09-28 Bristol Myers Squibb Co Moleculas de union al receptor ox40 de humano.
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP2328919A2 (en) 2008-08-25 2011-06-08 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
EP2358392B1 (en) 2008-11-12 2019-01-09 MedImmune, LLC Antibody formulation
HUE034832T2 (hu) 2008-12-09 2021-12-28 Hoffmann La Roche Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
ES2646863T3 (es) 2009-11-24 2017-12-18 Medimmune Limited Agentes de unión específica contra B7-H1
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
MY171312A (en) 2010-08-23 2019-10-08 Univ Texas Anti-ox40 antibodies and methods of using the same
JP6220774B2 (ja) 2011-03-31 2017-10-25 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Ｉｃｏｓに対する抗体及びその使用
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
CN103842030B (zh) 2011-08-01 2018-07-31 霍夫曼-拉罗奇有限公司 使用pd-1轴结合拮抗剂和mek抑制剂治疗癌症的方法
CN103946238B (zh) 2011-08-23 2016-10-12 德克萨斯州立大学董事会 抗ox40抗体及使用其的方法
JP6138813B2 (ja) 2011-11-28 2017-05-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗ｐｄ−ｌ１抗体及びその使用
EP2850102A1 (en) 2012-05-15 2015-03-25 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
CN107892719B (zh) 2012-10-04 2022-01-14 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法
SG10202108879SA (en) 2014-02-10 2021-09-29 Merck Patent Gmbh TARGETED TGFβ INHIBITION
MX2018015483A (es) * 2016-06-13 2019-03-18 Glaxosmithkline Ip Dev Ltd Piridinas sustituidas como inhibidores de adn metiltransferasa-1 (dnmt1).

Also Published As

Publication number Publication date
US20230101987A1 (en) 2023-03-30
IL305427A (en) 2023-10-01
CN116917273A (zh) 2023-10-20
KR20230154230A (ko) 2023-11-07
CA3212345A1 (en) 2022-09-09
US20240180933A1 (en) 2024-06-06
JP2024509529A (ja) 2024-03-04
BR112023017296A2 (pt) 2023-11-14
US11771711B2 (en) 2023-10-03
WO2022185160A1 (en) 2022-09-09
TW202302535A (zh) 2023-01-16
EP4301733A1 (en) 2024-01-10
CO2023011641A2 (es) 2023-09-18
AU2022230795A1 (en) 2023-09-21
CL2023002577A1 (es) 2024-01-26
AR124975A1 (es) 2023-05-24

Similar Documents

Publication Publication Date Title
PH12020551927A1 (en) Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
CR20220584A (es) Inhibidores de kras tricíclicos fusionados
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
PH12020550216A1 (en) Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
MX2022002938A (es) Compuestos inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) cooperativos para metiltioadenosina (mta).
PH12018502633A1 (en) Substituted pyridines as inhibitors of dnmt1
PH12019501443A1 (en) Benzooxazole derivatives as immunomodulators
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
JOP20200342A1 (ar) مشتقات بيرازين مدمجة كمثبطات a2a/a2b
CR20220169A (es) Heterociclos bicíclicos como inhibidores de fgfr
MX2017015938A (es) Inhibidores de ezh2 para el tratar linfomas.
AU2018243463A8 (en) 11,13-modified saxitoxins for the treatment of pain
MX2021010888A (es) Derivados heteroaromaticos y aromaticos heterobiciclicos para el tratamiento de trastornos relacionados con ferroptosis.
BR112018007128A2 (pt) compostos para a inibição de câncer e epigênese
MX2021002916A (es) Pirfenidona enriquecida con deuterio y métodos para su uso.
MX2023003678A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
WO2020231739A3 (en) Compounds and methods for treating cancer
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
MX2023010067A (es) Piridinas sustituidas como inhibidores de dnmt1.
MX2021012543A (es) Compuestos de indoles quirales y su uso.
MX2022013398A (es) Compuestos de tetrahidroisoquinolina como activadores de nrf2.
MX2020008082A (es) Compuestos y composiciones para el tratamiento del dolor.